|
Feb 10
|
30 Most Valuable Drug Companies in 2024
|
|
Feb 9
|
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
|
|
Feb 9
|
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
|
|
Feb 9
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
|
|
Jan 19
|
Bill Gates, will.i.am, top execs on AI: Davos best moments
|
|
Jan 19
|
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
|
|
Jan 19
|
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
|
|
Jan 19
|
Novartis details first-line data for radiopharma drug Lutathera
|
|
Jan 18
|
Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Jan 18
|
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
|
|
Jan 18
|
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
|
|
Jan 17
|
Bill Gates, Nasdaq, Verizon CEOs on AI: Davos highlights
|
|
Jan 17
|
Novartis CEO explains how AI will impact drug development
|
|
Jan 17
|
Zacks Investment Ideas feature highlights: Eli Lilly and Novartis
|
|
Jan 16
|
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
|
|
Jan 16
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.
|
|
Jan 12
|
Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jan 12
|
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
|
|
Jan 11
|
Novartis (NVS) Gains As Market Dips: What You Should Know
|
|
Jan 11
|
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
|